Heron Therapeutics Inc. (HRTX) stock rose during pre-market. Let’s find out why?


Heron Therapeutics Inc. (NASDAQ: HRTX) stock surged by 11.38% at last close while the HRTX stock price gains by 7.53% in the pre-market trading session. Heron Therapeutics is an advertising biotechnology business dedicated to improving patients’ lives by discovering best-in-class therapies for some of the most serious unmet medical needs.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


HRTX stock’ Significant Update

The company reported that FDA has accepted a supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution, allowing the company to dramatically broaden the indication. ZYNRELEF is now approved for soft tissue or periarticular installation in adults to provide up to 72 hours of postsurgical analgesia.

ZYNRELEF is the first-ever medication for surgical pain control that has been carefully examined in Phase 3 studies and shown to be better than the existing regular solution, bupivacaine solution. When contrasted to bupivacaine solution, ZYNRELEF provided greater, prolonged postoperative pain management for up to 72 hours and reduced the requirement for opioids, with more patients opioid-free. The FDA has validated that ZYNRELEF’s better efficacy exhibited in pivotal trials justifies its use in a larger spectrum of related surgical procedures with its approval.

ZYNRELEF’s increased indication will now cover about 7 million treatments each year. The use of ZYNRELEF in additional treatments allows doctors to minimize their patients’ requirement for opioids after surgery, which can have a good influence on the individuals and limit postoperative opioids that can contribute to overuse.


Postoperative opioids have been proved to be a gateway to addiction, with more than 2 million American citizens becoming chronic opioid users as a result of getting opioids after the operation. The largest number of fatal overdoses on record happened during the 12-month period ending April 2021, as per the Centers for Disease Control and Prevention, with over 100,000 Americans losing their lives.

Heron aims to file a new sNDA to the FDA in the second half of 2022 to establish a broad indication for soft tissue and orthopaedic surgical procedures, covering the complete 14 million target operations.


Please enter your comment!
Please enter your name here